Mall of America

Urethral Cancer Drugs Pipeline Guide 2022: Key Players, Developments and Established Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Friday, June 24, 2022
Pharmaceutical, Health, Oncology, R, Mall of America, Therapy, ROA, Urethral cancer

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities

Key Points: 
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
    The pipeline guide evaluates Urethral Cancer therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
    Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies

Geographic Atrophy Drugs in Development Pipeline Guide 2022 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 24, 2022
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Molecule, Geographic atrophy, R, Mall of America, Decision-making, Therapy, Key, Administration, History, News, Research, Route of administration, Target, Fine chemical, Medical device

The "Geographic Atrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Geographic Atrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information on the therapeutics under development for Geographic Atrophy, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
    The pipeline guide evaluates Geographic Atrophy therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
    Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies

Vulvar Cancer Drugs Market Pipeline Report 2022: Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Friday, June 24, 2022
Pharmaceutical, Health, Oncology, Molecule, Mall of America, Decision-making, Administration, Research, Target, R, Vulvar cancer, Key, History, D, Therapy, SEC, News, Route of administration, Pharmaceutical industry, Medical device

The "Vulvar Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vulvar Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information on the therapeutics under development for Vulvar Cancer, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases.
  • Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

Peripheral T-Cell Lymphomas Drugs Market Pipeline Report 2022: Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Friday, June 24, 2022
Pharmaceutical, Health, Oncology, Molecule, Mall of America, Decision-making, Peripheral T-cell lymphoma not otherwise specified, Administration, Research, PTCL, Peripheral, Target, R, Key, History, D, Therapy, SEC, News, Route of administration, Pharmaceutical industry, Medical device

The "Peripheral T-Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Peripheral T-Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases.
  • Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Drugs Development Report 2022: 21 Molecules with Approximately 15 Molecules Developed by Companies, Remaining by Universities - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022
Biotechnology, Pharmaceutical, Health, Molecule, Discovery, R, Therapy, Heme, Cerebellar ataxia, Mall of America, FXN, Protein, Cardiomyopathy, SEC, Central nervous system, EC, Fine chemical

The "Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
  • Frataxin Mitochondrial - Drugs In Development 2022 outlays comprehensive information on the Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Frataxin is a protein encoded by the FXN gene.
  • Furthermore, this report also reviews key players involved in Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics development with respective active and dormant or discontinued projects.

Genital Herpes Drugs Development Research Report 2022: Descriptive Licensing and Collaboration Details, R&D Brief, MoA & Developmental Activities - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022
Health, Pharmaceutical, Molecule, Discovery, R, Genital herpes, Therapy, Decision-making, Health care, Mall of America, Infection, Research, Company, Medication, News, SEC, History, Target, Pharmaceutical industry, Surveying, Marketing

The "Genital Herpes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genital Herpes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
  • The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
  • The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

Respiratory Syncytial Virus (RSV) Fusion Protein Drugs Market Pipeline Report 2022: Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022
Health, Pharmaceutical, Molecule, R, Research, Route of administration, Mall of America, Therapy, Administration, News, History, Decision-making, SEC, Research and development, Key, RSV, Product description, Vaccine, Pharmaceutical industry

The "Respiratory Syncytial Virus Fusion Protein Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Syncytial Virus Fusion Protein Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
  • Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics development and features dormant and discontinued projects.

Metastatic Prostate Cancer Drugs Market Pipeline Report 2022: Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022
Pharmaceutical, Health, Oncology, Molecule, R, Route of administration, Prostate, Therapy, Administration, Decision-making, Mall of America, Research, News, SEC, History, D, Target, Key, Pharmaceutical industry, Medical device

The "Metastatic Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Metastatic Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information on the therapeutics under development for Metastatic Prostate Cancer, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases.
  • Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

Cells Expressing T Cell Surface Glycoprotein CD4 Drugs Market Pipeline Report 2022: Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022
Biotechnology, Pharmaceutical, Health, Molecule, R, Route of administration, Therapy, Administration, Decision-making, Product description, Research, CD4, Mall of America, News, SEC, Research and development, History, Key, Pharmaceutical industry, Cell

The "Cells Expressing T Cell Surface Glycoprotein CD4 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cells Expressing T Cell Surface Glycoprotein CD4 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
  • Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Cells Expressing T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics development and features dormant and discontinued projects.

T Cell Surface Glycoprotein CD4 Drugs Market Pipeline Report 2022: Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022
Biotechnology, Pharmaceutical, Health, Molecule, R, Route of administration, Therapy, Administration, Decision-making, Product description, Research, CD4, Mall of America, News, SEC, Research and development, History, Key, Pharmaceutical industry

The "T Cell Surface Glycoprotein CD4 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "T Cell Surface Glycoprotein CD4 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
  • Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics development and features dormant and discontinued projects.